ERBB2 and breast cancer: The largest study testing the ability of gBRCA1/2m status to predict response to platinum salts was the ‘TNT’ Triple-Negative Breast Cancer Trial.44,45 Enroled patients (n = 376) had recurrent, locally advanced or metastatic BC that was confirmed to be triple-negative or occurred in a known BRCA1/2m carrier (regardless of ER, PgR, or HER2 status).